ZA200306648B - Cyano-substituted dihydropyrimidine compounds and their use to treat diseases. - Google Patents

Cyano-substituted dihydropyrimidine compounds and their use to treat diseases. Download PDF

Info

Publication number
ZA200306648B
ZA200306648B ZA200306648A ZA200306648A ZA200306648B ZA 200306648 B ZA200306648 B ZA 200306648B ZA 200306648 A ZA200306648 A ZA 200306648A ZA 200306648 A ZA200306648 A ZA 200306648A ZA 200306648 B ZA200306648 B ZA 200306648B
Authority
ZA
South Africa
Prior art keywords
methyl
cyano
dihydro
phenyl
pyrimidinecarboxylic acid
Prior art date
Application number
ZA200306648A
Other languages
English (en)
Inventor
Louis J Lombardo
Laurence I Wu
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of ZA200306648B publication Critical patent/ZA200306648B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200306648A 2001-03-29 2003-08-26 Cyano-substituted dihydropyrimidine compounds and their use to treat diseases. ZA200306648B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27995601P 2001-03-29 2001-03-29

Publications (1)

Publication Number Publication Date
ZA200306648B true ZA200306648B (en) 2004-11-26

Family

ID=23071059

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA200306648A ZA200306648B (en) 2001-03-29 2003-08-26 Cyano-substituted dihydropyrimidine compounds and their use to treat diseases.
ZA200307320A ZA200307320B (en) 2001-03-29 2003-09-18 Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA200307320A ZA200307320B (en) 2001-03-29 2003-09-18 Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases.

Country Status (26)

Country Link
US (1) US6809102B2 (zh)
EP (1) EP1373221A4 (zh)
JP (1) JP2005504725A (zh)
KR (1) KR20030086327A (zh)
CN (1) CN1507435A (zh)
AR (1) AR034585A1 (zh)
BG (1) BG108180A (zh)
BR (1) BR0208405A (zh)
CA (1) CA2442482A1 (zh)
CZ (1) CZ20032645A3 (zh)
EE (1) EE200300474A (zh)
HR (1) HRP20030875A2 (zh)
HU (1) HUP0400350A3 (zh)
IL (1) IL157441A0 (zh)
IS (1) IS6967A (zh)
MX (1) MXPA03008634A (zh)
NO (1) NO20034300L (zh)
PE (1) PE20021013A1 (zh)
PL (1) PL373759A1 (zh)
RU (1) RU2003130961A (zh)
SK (1) SK11062003A3 (zh)
TW (1) TWI228416B (zh)
UY (1) UY27232A1 (zh)
WO (1) WO2002079149A2 (zh)
YU (1) YU75803A (zh)
ZA (2) ZA200306648B (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900214B2 (en) * 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
CA2469801C (en) * 2001-12-11 2011-06-21 Kyowa Hakko Kogyo Co., Ltd. Thiadiazoline derivative
ES2326647T3 (es) * 2003-03-07 2009-10-16 Astrazeneca Ab Heterociclos condensados y sus usos.
AR050920A1 (es) * 2003-03-07 2006-12-06 Astrazeneca Ab Enantiomeros de heterociclos fusionados seleccionados y usos de los mismos
WO2004092147A1 (ja) 2003-04-18 2004-10-28 Kyowa Hakko Kogyo Co., Ltd. Ｍ期キネシン阻害剤
WO2004111024A1 (ja) * 2003-06-10 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. チアジアゾリン誘導体
US7166603B2 (en) 2003-07-23 2007-01-23 Bristol-Myers Squibb Co. Dihydropyrimidone inhibitors of calcium channel function
WO2005007124A2 (en) 2003-07-23 2005-01-27 Bristol-Myers Squibb Company Substituted dihydropyrimidine inhibitors of calcium channel function
JP2007509074A (ja) * 2003-10-16 2007-04-12 サイトキネティクス・インコーポレーテッド 化合物、組成物、および方法
AU2005263969A1 (en) * 2004-07-22 2006-01-26 Astrazeneca Ab Fused pyrimidones useful in the treatment and the prevention of cancer
US20060041128A1 (en) * 2004-08-18 2006-02-23 Astrazeneca Ab Selected fused heterocyclics and uses thereof
US20080293744A1 (en) * 2004-08-18 2008-11-27 Astrazeneca Ab Enantiomers of Selected Fused Pyrimidones and Uses in the Treatment and Prevention of Cancer
WO2006060737A2 (en) * 2004-12-03 2006-06-08 Takeda San Diego, Inc. Mitotic kinesin inhibitors
TW200720265A (en) * 2005-03-22 2007-06-01 Kyowa Hakko Kogyo Kk Agent for treatment of hematopoietic tumor
US20080194653A1 (en) * 2005-03-22 2008-08-14 Kyowa Hakko Kogyo Co., Ltd. Therapeutic Agent For Solid Tumor
EP1908755A4 (en) * 2005-06-24 2009-06-24 Kyowa Hakko Kirin Co Ltd THERAPEUTIC AGENT AGAINST RESTENOSIS
DE102006002065B4 (de) * 2006-01-16 2007-11-29 Infineon Technologies Austria Ag Kompensationsbauelement mit reduziertem und einstellbarem Einschaltwiderstand
CN110464722B (zh) * 2019-06-06 2023-05-23 暨南大学 一类小分子化合物或其药学上可接受的盐在制备抗肿瘤转移药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6211198B1 (en) 1993-04-05 2001-04-03 Synaptic Pharmaceutical Corporation Dihydropyridines and new uses thereof
EE9700209A (et) 1994-11-16 1998-04-15 Synaptic Pharmaceutical Corporation Dihüdropürimidiinid ja nende kasutamine
WO1997017969A1 (en) 1995-11-16 1997-05-22 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
CA2253862A1 (en) 1996-05-16 1997-11-20 Wai C. Wong Dihydropyrimidines and uses thereof
US6172066B1 (en) 1996-05-16 2001-01-09 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6080760A (en) 1997-06-18 2000-06-27 Merck & Co., Inc. Alpha 1A adrenergic receptor antagonists
CA2294349A1 (en) 1997-06-18 1998-12-23 Michael A. Patane Alpha 1aadrenergic receptor antagonists
AU1403099A (en) 1997-11-14 1999-06-07 Merck & Co., Inc. Alpha-1a adrenergic receptor antagonists
AU768834B2 (en) 1998-04-01 2004-01-08 Yale University A method for selectively modulating the interactions between survivin and tubulin
US6300084B1 (en) 1998-10-08 2001-10-09 The Regents Of The University Of California Anti-mitotic agent screening process
AUPQ171999A0 (en) 1999-07-20 1999-08-12 University Of Sydney, The Neurotropic virus transport
DE19935303A1 (de) 1999-07-28 2001-02-08 Aventis Pharma Gmbh Oligonukleotide zur Inhibierung der Expression von humanem eg5
CZ20021428A3 (cs) 1999-10-27 2002-11-13 Cytokinetics, Inc. Způsoby a kompozice vyuľívající chinazoliny
US6617115B1 (en) 1999-10-27 2003-09-09 Cytokinetics, Inc. Methods of screening for modulators of cell proliferation
US6284480B1 (en) 2000-04-03 2001-09-04 Cytokinetics, Inc. Antifungal assay
US6900214B2 (en) 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases

Also Published As

Publication number Publication date
US6809102B2 (en) 2004-10-26
EP1373221A4 (en) 2004-09-29
BG108180A (en) 2004-09-30
EP1373221A2 (en) 2004-01-02
IS6967A (is) 2003-09-24
SK11062003A3 (sk) 2004-08-03
EE200300474A (et) 2003-12-15
HRP20030875A2 (en) 2004-08-31
AR034585A1 (es) 2004-03-03
RU2003130961A (ru) 2005-04-10
NO20034300L (no) 2003-11-07
BR0208405A (pt) 2004-03-30
HUP0400350A2 (hu) 2005-01-28
PL373759A1 (en) 2005-09-05
CA2442482A1 (en) 2002-10-10
WO2002079149A2 (en) 2002-10-10
ZA200307320B (en) 2004-12-20
TWI228416B (en) 2005-03-01
YU75803A (sh) 2006-05-25
WO2002079149A3 (en) 2003-02-27
CZ20032645A3 (cs) 2004-06-16
HUP0400350A3 (en) 2005-06-28
IL157441A0 (en) 2004-03-28
US20030008888A1 (en) 2003-01-09
CN1507435A (zh) 2004-06-23
KR20030086327A (ko) 2003-11-07
NO20034300D0 (no) 2003-09-26
PE20021013A1 (es) 2002-11-10
UY27232A1 (es) 2002-11-29
MXPA03008634A (es) 2003-12-08
JP2005504725A (ja) 2005-02-17

Similar Documents

Publication Publication Date Title
US6900214B2 (en) Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
ZA200306648B (en) Cyano-substituted dihydropyrimidine compounds and their use to treat diseases.
RU2632907C2 (ru) Дейтерированные диаминопиримидиновые соединения и фармацевтические композиции, содержащие такие соединения
US20030232832A1 (en) Pyrrolotriazinone compounds and their use to teat diseases
JP6321039B2 (ja) 五員かつ六員複素環式化合物並びにその製造方法、医薬品組成物及びその使用
CA2442455A1 (en) A method of treating proliferative diseases using eg5 inhibitors
WO2004106492A2 (en) Bicyclicpyrimidones and their use to treat diseases
AU2010224523A1 (en) Novel anti-inflammatory agents
KR20100116206A (ko) Ｈｓｐ90 저해제로서의 옥심 유도체
CA2538026A1 (en) Crf antagonists and heterobicyclic compounds
CN112313207B (zh) 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用
JPH08225535A (ja) インダゾール誘導体
WO2006009245A1 (ja) 含窒素縮合二環式化合物
JP4778890B2 (ja) 置換された２−（ジアザ−ビシクロ−アルキル）−ピリミドン誘導体
AU2002303169A1 (en) Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
AU2002258636A1 (en) Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases
AU2002248724A1 (en) A method of treating proliferative diseases using Eg5 inhibitors